Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines

Cancer Res Commun. 2024 Dec 1;4(12):3084-3098. doi: 10.1158/2767-9764.CRC-24-0316.

Abstract

HRD is common in cancer and can be exploited therapeutically, as it sensitizes cells to DNA-damaging agents. Here, we scored more than 1,300 cancer cell lines for HRD using two different bioinformatic approaches, thereby enabling large-scale analyses that provide insights into the etiology and features of HRD.

MeSH terms

  • Cell Line, Tumor
  • Computational Biology
  • Homologous Recombination* / genetics
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / pathology